Search results for "HOMA"

showing 10 items of 956 documents

Splenic marginal zone lymphoma with or without villous lymphocytes

2004

BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical-pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male-to-female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found i…

AdultMaleCancer Researchmedicine.medical_specialtyLymphomaAnemiamedicine.medical_treatmentSplenectomysplenic marginal zone lymphomaGastroenterologyBone marrow biopsyIntrasinusoidalInternal medicinemedicineHumansLymphocytesLeukocytosisSplenic marginal zone lymphomaSurvival rateAgedAged 80 and overLeukopeniabusiness.industrySplenic Neoplasmssplenic marginal zone lymphoma; PrognosisSplenic lymphoma with villous lymphocytesMiddle AgedPrognosismedicine.diseaseSplenic NeoplasmSurgerySurvival Ratemedicine.anatomical_structureOncologySplenectomySplenic lymphoma with villous lymphocyteLymphocyteFemaleBone marrowmedicine.symptombusinessHumanCancer
researchProduct

Cytogenetic findings in secondary acute nonlymphocytic leukemia

1992

Abstract We here report the results of cytogenetic studies carried out in eight patients with acute nonlymphocytic leukemia developed after primary neoplasias. In seven of the reported cases, clonal chromosome aberrations were found, some being specific of de novo acute nonlymphocytic leukemia (ANLL). Numerical abnormalities were detected, such as the total monosomy of chromosomes 5, 7, 21, trisomy of chromosomes 8, 11, 15, and duplication of chromosome Y. Structural changes were also observed: a del(12)(p12), a del(16)(q22), the translocations t(3;5)(p21;q35),t(3;7)(p21;q35), and t(12;14)(p12;q32) and other changes involving chromosome 8. The finding of a hypertetraploid karyotype with com…

AdultMaleCancer Researchmedicine.medical_specialtyMonosomyChromosomal translocationBiologyTranslocation GeneticPolyploidyMonosomyhemic and lymphatic diseasesGeneticsmedicineHumansMolecular BiologyAgedChromosome AberrationsCytogeneticsChromosomeNeoplasms Second PrimaryKaryotypeMiddle Agedmedicine.diseaseLymphomaLeukemia Myeloid AcuteLeukemiaImmunologyCancer researchChromosomes Human Pair 5FemaleTrisomyChromosomes Human Pair 7Cancer Genetics and Cytogenetics
researchProduct

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.disease_causeCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineCEBPAmedicineHumansneoplasmsAgedMutationHematologybusiness.industryMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseLymphomaGATA2 Transcription FactorHaematopoiesisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureOncology030220 oncology & carcinogenesisMutationCancer researchCCAAT-Enhancer-Binding ProteinsFemalebusiness030215 immunologyLeukemia
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lym…

2011

Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), i.e. CPOP (cyclophosphamide, pixantrone, vincristine, and prednisone), in patients with relapsed aNHL who had previously received CHOP ± rituximab. Patients were administered pixantrone on day 1 of each 21-day cycle. Phase I (n = 35) dose escalation from 80 mg/m(2) to 180 mg/m(2) established the phase II (n = 30) dose as 150 mg/m(2). In phase II, 20 patients (67%) received all…

AdultMaleCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidePhases of clinical researchAntineoplastic AgentsPharmacologyGastroenterologychemistry.chemical_compoundPrednisoneRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedNeoplasm StagingAged 80 and overPixantronebusiness.industryLymphoma Non-HodgkinHematologyMiddle Agedmedicine.diseaseIsoquinolinesSurvival AnalysisTreatment OutcomeOncologychemistryVincristinePrednisoneMantle cell lymphomaFemalebusinessDiffuse large B-cell lymphomaFebrile neutropeniaImmunosuppressive Agentsmedicine.drugLeukemialymphoma
researchProduct

Temsirolimus for the treatment of mantle cell lymphoma.

2010

Although recent progress has been made in the treatment of mantle cell lymphoma (MCL) the majority of patients experience relapse and ultimately die of their disease. The translocation t(11;14) is a prerequisite for the diagnosis of MCL and results in overexpression of cyclin D1. Its protein translation is controlled by mTOR, a key element of the PI3K/Akt pathway, and mTOR constitutes an attractive therapeutic target. Temsirolimus, a specific inhibitor of mTOR, has been evaluated in two Phase II trials in patients with relapsed MCL, and promising response rates up to 40% were found. Subsequently, a randomized Phase III trial was initiated, in which superiority in remission induction and pro…

AdultMaleCombination therapyChromosomal translocationAntineoplastic AgentsLymphoma Mantle-CellPharmacologyDisease-Free SurvivalDrug Administration ScheduleCyclin D1hemic and lymphatic diseasesmedicineSecondary PreventionHumansCyclin D1PI3K/AKT/mTOR pathwayAgedAged 80 and overSirolimusClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesRemission InductionIntracellular Signaling Peptides and ProteinsHematologyMiddle Agedmedicine.diseaseTemsirolimusNon-Hodgkin's lymphomaRegimenCancer researchMantle cell lymphomaFemalebusinessmedicine.drugExpert review of hematology
researchProduct

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 + T Cells To Predict CMV DNAemia Clearance in …

2014

ABSTRACT It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8 + T cells) appeared to perform better for this purpose.

AdultMaleGanciclovirvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesClinical TherapeuticsViral Matrix ProteinsInterferon-gammamedicineHumansValganciclovirCytotoxic T cellPharmacology (medical)GanciclovirMultiple myelomaPharmacologybusiness.industryLymphoma Non-HodgkinAnemia Aplasticvirus diseasesValganciclovirMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaPhosphoproteinsmedicine.diseaseTransplant RecipientsLeukemia Myeloid AcuteLeukemiaInfectious DiseasesCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellMultiple MyelomabusinessCD8Stem Cell Transplantationmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Real-time spatial compound sonography of Achilles tendon in patients with heterozygous familial hypercholesterolaemia and normal physical examination

2007

This study was undertaken to assess the prevalence and ultrasound features of Achilles tendon xanthomas (ATX) in patients with heterozygous familial hypercholesterolemia (HFH) and normal physical examination studied with high-resolution ultrasonography (HRUS) and, secondarily, to evaluate the role of real-time spatial compound sonography (CS) in terms of image quality.Both Achilles tendons of 40 patients with HFH were studied with HRUS and CS. Two experienced radiologists evaluated by consensus the presence of ATX described as (1) tendon thickening and/or (2) focal hypoechoic areas and the quality of images obtained with the two techniques.Ten out of 80 tendons showed thickening (mean: 11.2…

AdultMaleHeterozygotemedicine.medical_specialtyAdolescentPhysical examinationFamilial hypercholesterolemiaAchilles TendonHyperlipoproteinemia Type IIMuscular DiseasesXanthomatosismedicineHumansRadiology Nuclear Medicine and imagingIn patientChildPhysical ExaminationAgedUltrasonographyNeuroradiologyAchilles tendonmedicine.diagnostic_testbusiness.industryUltrasoundInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseSurgerySonographymedicine.anatomical_structureFemaleUltrasonographybusinessLa radiologia medica
researchProduct

Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients

2017

Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol with co-dominant transmission and high risk of cardiovascular disease (CVD), although with high variability among subjects. Currently, CVD stratification tools for heterozygous FH (HeFH) are not available. A definition of severe HeFH has been recently proposed by the International Atherosclerosis Society (IAS), but it has not been validated. Our study aims to see clinical characteristics and prevalence of CVD in subjects defined as severe HeFH by IAS criteria. Probable or definite HeFH introduced in the Dyslipidemia Registry of Spanish Arteriosclerosis Society were analyzed by the IAS crite…

AdultMaleHeterozygotemedicine.medical_specialtyMultivariate analysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness IndexHyperlipoproteinemia Type IITendons03 medical and health sciences0302 clinical medicineMuscular DiseasesInternal medicineSeverity of illnessPrevalenceXanthomatosismedicineHumans030212 general & internal medicineUnivariate analysisbusiness.industryCholesterol LDLOdds ratioArteriosclerosisMiddle Agedmedicine.diseaseLogistic ModelsEndocrinologyCardiovascular DiseasesMultivariate AnalysisCardiologyFemaleCardiology and Cardiovascular MedicinebusinessRisk assessmentDyslipidemiaThe American Journal of Cardiology
researchProduct

Glut-1 Expression and In Situ CD1a/CD57 Immunologic Deficit in Keratoacanthoma and Squamous Cell Carcinoma of Immunocompetent Patients

2011

It is not easy to reach a differential diagnosis between keratoacanthoma (KA) and squamous cell carcinoma (SCC) and furthermore there is still considerable discussion about the relationship of these 2 tumors with immunity. To facilitate such a diagnosis, we assessed the Glut-1 antibody, reported to be strongly and diffusely expressed in SCC but never assessed in KA. We studied 43 lesions of immunocompetent patients: 17 SCCs, 13 typical KAs (tKAs), and 13 atypical KAs (aKAs), with histologic features of SCC in less than 30% of the lesions. In tKA, Glut-1 stained only the basal layers of the squamous nests (basal pattern) whereas in SCC the squamous nests were randomly and diffusely stained (…

AdultMaleKeratoacanthomaPathologymedicine.medical_specialtySkin NeoplasmsHistologySettore MED/08 - Anatomia PatologicaSkin DiseasesPathology and Forensic MedicineAntigens CD1Diagnosis DifferentialBasal (phylogenetics)CD57 AntigensAntigenBiomarkers TumorCarcinomamedicineHumansAgedAged 80 and overCD20biologybusiness.industryGlut-1 Keratoacanthoma Squamous cell carcinoma CD1aImmunityMiddle Agedmedicine.diseaseKeratoacanthomastomatognathic diseasesMedical Laboratory TechnologyExcitatory Amino Acid Transporter 2Carcinoma Squamous CellDisease Progressionbiology.proteinFemaleDifferential diagnosisSkin cancerbusinessCD8Applied Immunohistochemistry & Molecular Morphology
researchProduct